Skip to main content
. 2008 Nov 20;296(1):G129–G134. doi: 10.1152/ajpgi.90556.2008

Fig. 3.

Fig. 3.

Comparison of visceral nociception in wild-type mice receiving either ceftriaxone (CTX; 200 mg·kg−1·day−1 for 1 wk), an EAAT2 expression activator, or vehicle. A: representative Western blot of EAAT2 protein levels in the spinal cords of ceftriaxone- and vehicle (saline)-treated mice. ceftriaxone treatment enhanced EAAT2 protein expression ∼40–80%. B: effect of ceftriaxone treatment on the VMR to CRD. The 1-wk ceftriaxone-treated mice (n = 11) showed a 49–70% reduction in VMR, compared with vehicle-treated controls (n = 10). *P < 0.05; **P < 0.005.